Skip to main content
Top
Published in: Immunologic Research 4/2016

01-08-2016 | Original Article

Interleukin 27 is up-regulated in patients with active inflammatory bowel disease

Authors: Janette Furuzawa Carballeda, Gabriela Fonseca Camarillo, Jesús K. Yamamoto-Furusho

Published in: Immunologic Research | Issue 4/2016

Login to get access

Abstract

The aim of the study was to characterize and quantify tissue gene and protein expression of IL-27 in ulcerative colitis (UC) and Crohn’s disease (CD) patients. This is an observational and cross-sectional study. Fifty-four patients with IBD were studied: 27 active UC, 12 inactive UC, 10 active CD, and 5 inactive CD. All patients belonged to the Inflammatory Bowel Disease Clinic at the Instituto Nacional de Ciencias Médicas y Nutrición. We found that IL-27 gene expression was significantly higher in active UC versus inactive UC group (P = 0.015). The IL-27 mRNA expression was increased in patients with active CD compared with inactive CD disease (P = 0.035). The percentage of IL-27 immunoreactive cells was higher in active UC versus active CD patients and non-inflamed tissue controls. The IL-27 was significantly elevated in active UC and CD patients, and it was associated with disease severity.
Literature
2.
go back to reference Fonseca-Camarillo G, Yamamoto-Furusho JK. Interleukins involved in inflammatory bowel disease as new therapeutic targets. Curr Immunol Rev. 2013;9(2):86–92.CrossRef Fonseca-Camarillo G, Yamamoto-Furusho JK. Interleukins involved in inflammatory bowel disease as new therapeutic targets. Curr Immunol Rev. 2013;9(2):86–92.CrossRef
3.
go back to reference Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol. 2010;7(2):110–7.CrossRefPubMed Melmed GY, Targan SR. Future biologic targets for IBD: potentials and pitfalls. Nat Rev Gastroenterol Hepatol. 2010;7(2):110–7.CrossRefPubMed
4.
go back to reference Boulay JL, O’Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 2003;19(2):159–63.CrossRefPubMed Boulay JL, O’Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity. 2003;19(2):159–63.CrossRefPubMed
5.
go back to reference Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004;173(2):715–20.CrossRefPubMed Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004;173(2):715–20.CrossRefPubMed
6.
go back to reference Murakami M, Kamimura D, Hirano T. New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27. Growth Factors. 2004;22(2):75–7.CrossRefPubMed Murakami M, Kamimura D, Hirano T. New IL-6 (gp130) family cytokine members, CLC/NNT1/BSF3 and IL-27. Growth Factors. 2004;22(2):75–7.CrossRefPubMed
7.
go back to reference Hölscher C. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol. 2004;193(1):1–17.CrossRefPubMed Hölscher C. The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases. Med Microbiol Immunol. 2004;193(1):1–17.CrossRefPubMed
8.
go back to reference Yoh Matsumoto. Is interleukin-27 a real candidate for immunotherapies of multiple sclerosis? Clin Exp Neuroimmunol. 2013;4(1):7–9.CrossRef Yoh Matsumoto. Is interleukin-27 a real candidate for immunotherapies of multiple sclerosis? Clin Exp Neuroimmunol. 2013;4(1):7–9.CrossRef
9.
go back to reference Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G568–76.CrossRefPubMed Sasaoka T, Ito M, Yamashita J, Nakajima K, Tanaka I, Narita M, Hara Y, Hada K, Takahashi M, Ohno Y, Matsuo T, Kaneshiro Y, Tanaka H, Kaneko K. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G568–76.CrossRefPubMed
10.
go back to reference Sutherland LR, Martin F, Greer Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-aminosalicylicacid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894–8.CrossRefPubMed Sutherland LR, Martin F, Greer Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-aminosalicylicacid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894–8.CrossRefPubMed
11.
go back to reference Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, Vatn MH, Moum B. Ulcerative colitis and clinical course: results of a 5-year population based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.CrossRefPubMed Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, Vatn MH, Moum B. Ulcerative colitis and clinical course: results of a 5-year population based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12:543–50.CrossRefPubMed
12.
13.
go back to reference Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94(6):1383–9.CrossRefPubMed Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94(6):1383–9.CrossRefPubMed
14.
go back to reference Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, Wu Y, Mayo L, Ben-Hamo R, Efroni S, Kuchr. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol. 2013;14(10):1054–1063.CrossRefPubMedPubMedCentral Mascanfroni ID, Yeste A, Vieira SM, Burns EJ, Patel B, Sloma I, Wu Y, Mayo L, Ben-Hamo R, Efroni S, Kuchr. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol. 2013;14(10):1054–1063.CrossRefPubMedPubMedCentral
15.
go back to reference Wynick C, Petes C, Gee K. Interleukin-27 mediates inflammation during chronic disease. J Interferon Cytokine Res. 2014;34(10):741–9.CrossRefPubMed Wynick C, Petes C, Gee K. Interleukin-27 mediates inflammation during chronic disease. J Interferon Cytokine Res. 2014;34(10):741–9.CrossRefPubMed
16.
go back to reference Visperas A, Do JS, Bulek K, Li X, Min B. IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol. 2014;7(3):625–33.CrossRefPubMed Visperas A, Do JS, Bulek K, Li X, Min B. IL-27, targeting antigen-presenting cells, promotes Th17 differentiation and colitis in mice. Mucosal Immunol. 2014;7(3):625–33.CrossRefPubMed
17.
go back to reference Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11(1):16–23.CrossRefPubMed Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis. 2005;11(1):16–23.CrossRefPubMed
18.
go back to reference Yamamoto-Furusho JK, Posadas-Sánchez R, Alvarez-León E, Vargas-Alarcón G. Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. Immunol Lett. 2016;172:79–83.CrossRefPubMed Yamamoto-Furusho JK, Posadas-Sánchez R, Alvarez-León E, Vargas-Alarcón G. Protective role of Interleukin 27 (IL-27) gene polymorphisms in patients with ulcerative colitis. Immunol Lett. 2016;172:79–83.CrossRefPubMed
Metadata
Title
Interleukin 27 is up-regulated in patients with active inflammatory bowel disease
Authors
Janette Furuzawa Carballeda
Gabriela Fonseca Camarillo
Jesús K. Yamamoto-Furusho
Publication date
01-08-2016
Publisher
Springer US
Published in
Immunologic Research / Issue 4/2016
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8804-z

Other articles of this Issue 4/2016

Immunologic Research 4/2016 Go to the issue